CEO
RT
RevOpsis Therapeutics
RevOpsis Therapeutics utilizes the RevMod Platform for the rapid discovery and development of multi-specific biologics targeting retinal vascular diseases. Their lead product, a TriMod biologic, aims to improve disease outcomes and extend remission periods for patients experiencing vision loss.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$17.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Ronil Patel
CBO
Product
Problem
Retinal vascular diseases are complex and multifactorial, often requiring treatments that address multiple biological pathways simultaneously. Current therapies may not adequately target all relevant pathways, leading to suboptimal disease outcomes and limited remission periods for patients experiencing vision loss.
Solution
RevOpsis Therapeutics is developing multi-specific biologics for retinal vascular diseases using its proprietary RevMod Platform. This platform enables the rapid discovery and development of novel therapies designed to target dominant biological pathways involved in these complex diseases. Their lead product is a first-in-class TriMod biologic specifically engineered to improve disease outcomes and extend remission periods for patients. The RevMod platform offers a modular, plug-and-play system for efficiently designing multi-specific biologics.
Target Audience
The primary target audience includes patients suffering from retinal vascular diseases and the ophthalmologists and retinal specialists who treat them.
Features
- RevMod Platform: A modular system for rapid discovery and development of multi-specific biologics.
- TriMod Biologic: A first-in-class therapeutic candidate targeting retinal vascular diseases.
- Designed to target multiple dominant biological pathways simultaneously.
- Aims to improve disease outcomes and extend remission periods.
- Platform allows for efficient design of MultiMod biologics.